Cargando…

Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice

Several vaccines have demonstrated efficacy against SARS-CoV-2 mediated disease, yet there is limited data on the immune response induced by heterologous vaccination regimens using alternate vaccine modalities. Here, we present a detailed description of the immune response, in mice, following vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spencer, Alexandra J., McKay, Paul F., Belij-Rammerstorfer, Sandra, Ulaszewska, Marta, Bissett, Cameron D., Hu, Kai, Samnuan, Karnyart, Blakney, Anna K., Wright, Daniel, Sharpe, Hannah R., Gilbride, Ciaran, Truby, Adam, Allen, Elizabeth R., Gilbert, Sarah C., Shattock, Robin J., Lambe, Teresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129084/ https://www.ncbi.nlm.nih.gov/pubmed/34001897 http://dx.doi.org/10.1038/s41467-021-23173-1

Ejemplares similares

The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world
por: Sharpe, Hannah R., et al.
Publicado: (2020)

Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model
por: Saunders, Jack E., et al.
Publicado: (2023)

Innate Inhibiting Proteins Enhance Expression and Immunogenicity of Self-Amplifying RNA
por: Blakney, Anna K., et al.
Publicado: (2021)

Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines
por: Blakney, Anna K., et al.
Publicado: (2021)

Quality by design modelling to support rapid RNA vaccine production against emerging infectious diseases
por: van de Berg, Damien, et al.
Publicado: (2021)

The Integration of Human and Veterinary Studies for Better Understanding and Management of Crimean-Congo Haemorrhagic Fever
por: Gilbride, Ciaran, et al.
Publicado: (2021)

Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
por: McKay, Paul F., et al.
Publicado: (2020)

A self-amplifying RNA vaccine protects against SARS-CoV-2 (D614G) and Alpha variant of concern (B.1.1.7) in a transmission-challenge hamster model
por: Frise, Rebecca, et al.
Publicado: (2022)

A Multi-Filovirus Vaccine Candidate: Co-Expression of Ebola, Sudan, and Marburg Antigens in a Single Vector
por: Sebastian, Sarah, et al.
Publicado: (2020)

Polymer formulated self-amplifying RNA vaccine is partially protective against influenza virus infection in ferrets
por: McKay, P F, et al.
Publicado: (2022)

STING-pathway modulation to enhance the immunogenicity of adenoviral-vectored vaccines
por: Padron-Regalado, Eriko, et al.
Publicado: (2022)

Chimpanzee adenoviral vectors as vaccines for outbreak pathogens
por: Ewer, Katie, et al.
Publicado: (2017)

Presentation of antigen on extracellular vesicles using transmembrane domains from viral glycoproteins for enhanced immunogenicity
por: Hu, Kai, et al.
Publicado: (2022)

Safety and Immunogenicity of Homologous and Heterologous Adenoviral-Vectored and mRNA COVID-19 Vaccine Regimens in Radiotherapy Patients
por: Prayongrat, Anussara, et al.
Publicado: (2023)

Big Is Beautiful: Enhanced saRNA Delivery and Immunogenicity by a Higher Molecular Weight, Bioreducible, Cationic Polymer
por: Blakney, Anna K., et al.
Publicado: (2020)

A self-amplifying RNA vaccine provides protection in a murine model of bubonic plague
por: Shattock, Robin John, et al.
Publicado: (2023)

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques
por: van Doremalen, Neeltje, et al.
Publicado: (2020)

Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccines
por: Elliott, Tamara, et al.
Publicado: (2022)

Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study
por: Wanlapakorn, Nasamon, et al.
Publicado: (2022)

Immune response of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA COVID-19 vaccines in immunocompromised patients
por: Chu, Chang, et al.
Publicado: (2023)

An Update on Self-Amplifying mRNA Vaccine Development
por: Blakney, Anna K., et al.
Publicado: (2021)

Formulation, inflammation, and RNA sensing impact the immunogenicity of self-amplifying RNA vaccines
por: Tregoning, John S., et al.
Publicado: (2022)

Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data
por: Wanlapakorn, Nasamon, et al.
Publicado: (2022)

Heterologous vaccine regimens against COVID-19
por: Duarte-Salles, Talita, et al.
Publicado: (2021)

Generalized Modules for Membrane Antigens (GMMA), an outer membrane vesicle‐based vaccine platform, for efficient viral antigen delivery
por: Hu, Kai, et al.
Publicado: (2022)

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
por: van Doremalen, Neeltje, et al.
Publicado: (2020)

Tu1269: IMMUNOGENICITY AND SAFETY OF HETEROLOGOUS VERSUS HOMOLOGOUS PRIME-BOOST REGIMENS WITH ADENOVIRAL VECTORED AND MRNA SARS-COV-2 VACCINE IN LIVER TRANSPLANT RECIPIENTS
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2022)

Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model
por: van Doremalen, Neeltje, et al.
Publicado: (2022)

Potency of an HIV-SAM™ vaccine in a heterologous prime-boost vaccination regimen
por: Banerjee, K, et al.
Publicado: (2012)

Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster
por: Ulaszewska, Marta, et al.
Publicado: (2023)

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination
por: Sharpe, Hannah R., et al.
Publicado: (2022)

The Skin You Are In: Design-of-Experiments Optimization of Lipid Nanoparticle Self-Amplifying RNA Formulations in Human Skin Explants
por: Blakney, Anna K., et al.
Publicado: (2019)

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19
por: Graham, Simon P., et al.
Publicado: (2020)

Heterologous Boosting of Recombinant Adenoviral Prime Immunization With a Novel Vesicular Stomatitis Virus–vectored Tuberculosis Vaccine
por: Roediger, Elizabeth K, et al.
Publicado: (2008)

Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans
por: Capone, Stefania, et al.
Publicado: (2020)

The efficacy of the prime-boost regimen for heterologous infectious bronchitis vaccines mandates the administration of homologous vaccines
por: Al-Kubati, Anwar A. G., et al.
Publicado: (2022)

Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice
por: Bliss, Carly M., et al.
Publicado: (2019)

Immunogenicity and safety of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA SARS-CoV-2 vaccine in liver transplant recipients: a prospective study
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2022)

Progress in Adenoviral Capsid-Display Vaccines
por: Vujadinovic, Marija, et al.
Publicado: (2018)

Use of adenoviral vectors as veterinary vaccines
por: Ferreira, T B, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_t0o3119a1a2dnnkvb7dn86g6aq